GlassScriptPhysician profile
Gail R Jones
NPI 1467427146
$127,576.19
in general payments reported to CMS, 2019-2025
32 companies · $639 in 2025
The $639 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $27K · 2021: $25K · 2022: $25K · 2023: $732 · 2024: $10K · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Food and Beverage | $2,049.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cryo Specialty Medical, LLC | $120,500.00 | 2019-2024 | |
| Teleflex LLC | $1,202.31 | 2021 | |
| Astellas Pharma US INC | $586.52 | 2019-2024 | Veozah |
| Janssen Biotech, INC. | $525.68 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $465.65 | 2019-2024 | Provenge |
| Myriad Genetic Laboratories, INC. | $443.05 | 2020-2025 | Myrisk, Prolaris |
| Myovant Sciences INC. | $437.09 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $409.26 | 2019-2023 | Xiaflex, Aveed |
| Antares Pharma, INC. | $391.77 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Allergan, INC. | $377.59 | 2019-2021 | |
| Axonics, INC. | $327.38 | 2021-2023 | Axonics |
| Tolmar, INC. | $251.93 | 2023-2025 | Jatenzo |
| Sumitomo Pharma America, INC. | $226.71 | 2023-2025 | Orgovyx, Gemtesa |
| Amgen INC. | $176.76 | 2019-2021 | |
| Boston Scientific Corporation | $148.48 | 2020-2025 | Ams 700 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.41 | 2019-2022 | |
| Endo USA, INC. | $121.13 | 2024-2025 | Xiaflex |
| Blue Earth Diagnostics | $114.17 | 2020-2022 | |
| Pfizer INC. | $95.20 | 2019-2020 | |
| Urovant Sciences INC | $81.11 | 2021-2022 | |
| Neotract INC. | $80.38 | 2019 | |
| Urogen Pharma, INC. | $66.42 | 2020-2025 | |
| Coloplast Corp | $64.34 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.61 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $59.18 | 2020-2025 | Keytruda |
| Verity Pharmaceuticals INC. | $49.95 | 2024-2025 | Tlando |
| Ferring Pharmaceuticals INC. | $49.84 | 2019-2020 | |
| Halozyme INC | $37.34 | 2023 | |
| Baudax Bio INC. | $22.57 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $22.45 | 2021 | |
| Janssen Scientific Affairs, LLC | $21.55 | 2019 | |
| Clovis Oncology, INC. | $16.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$367,464.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gail Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.